Seguridad del tratamiento con surfactante pulmonar en el síndrome de dificultad respiratoria aguda en niños

Rodríguez-Moya, Valentín Santiago; Pérez, Yinet Barrese; Piña, Rolando Uranga; Pérez, Lianet Díaz; Sánchez, Leonor Verdecia; Díaz-Casañas, Elaine.
Rev. habanera cienc. méd ; 21(1)feb. 2022.
Artículo en Español | LILACS, CUMED | ID: biblio-1409447

Documentos relacionados

  1. Seguridad de abatacept en pacientes con artritis reumatoidea
  2. Target product profile: aerosolized surfactant for neonatal respiratory distress.
  3. Impact of surfactant when utilized during pediatric cardiac surgery admissions: analysis of a nationwide database.
  4. Bovine surfactant in the treatment of pneumonia-induced-neonatal acute respiratory distress syndrome (NARDS) in neonates beyond 34 weeks of gestation: a multicentre, randomized, assessor-blinded, placebo-controlled trial.
  5. Success of blinding a procedural intervention in a randomised controlled trial in preterm infants receiving respiratory support.
  6. Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome.
  7. [Efectividad de la suspensión bacteriana sublingual en la prevención de infecciones de vías aéreas de repetición en pediatría].
  8. Dose-Response Study on Surfactant Nebulization Therapy During Nasal Continuous Positive Airway Pressure Ventilation in Spontaneously Breathing Surfactant-Deficient Newborn Piglets.
  9. Randomized Trial of Surfactant Therapy via Laryngeal Mask Airway Versus Brief Tracheal Intubation in Neonates Born Preterm.
  10. Less Invasive Surfactant Administration (LISA) vs. Intubation Surfactant Extubation (InSurE) in Preterm Infants with Respiratory Distress Syndrome: A Pilot Randomized Controlled Trial.